Charles River works on rare disease gene therapy; Emergent gets $75M for anthrax vaccine; EuroAPI hires new COO
Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more.
Charles River and the Australian nonprofit Genetic Cures for Kids partnered on Tuesday to develop and manufacture a gene therapy for the hereditary neurodegenerative disease called spastic paraplegia type 56 (SPG56) by using Charles River’s plasmid production platform eXpDNA. SPG56 is a rare disease affecting children, leaving them unable to walk and talk independently.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.